International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer
M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Peter C. Black(University of British Columbia), Roger Buckley(Aurrion (United States)), Wassim Kassouf(McGill University), Ken Brothers(National Cancer Institute), Marc Colombel(Hôpital Edouard Herriot), J. Alfred Witjes(Radboud University Nijmegen), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Yair Lotan(Southwestern Medical Center), Seth P. Lerner(Baylor College of Medicine), Donald L. Lamm(The University of Texas System), Gary D. Steinberg(Rush University Medical Center), Trinity J. Bivalacqua(University of Pennsylvania), Andreas Böhle(Kinderkrebs-Zentrum Hamburg), Mark S. Soloway(Memorial Regional Hospital), Maurizio Brausi(De Agostini (Italy)), Richard Sylvester(European Organisation for Research and Treatment of Cancer), J. Palou-Redorta(Universitat Autònoma de Barcelona), Raj Persad(North Bristol NHS Trust)
Cited by 94
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k